BioMarin Advances Pediatric Growth Treatment with Promising Data on VOXZOGO and BMN 333

BioMarin Pharmaceutical Inc. (BMRN) continues to make significant strides in addressing growth disorders in children, as highlighted by new data at the recent ENDO 2026 conference in Chicago. The results from a Phase 2, investigator-sponsored extension study of VOXZOGO® (vosoritide) show promising sustained improvements in growth for young patients with hypochondroplasia over a three-year period. In this study involving 13 children, the mean height standard deviation score (SDS) increased notably by 0.72, while the annualized growth velocity (AGV) jumped from 4.27 cm/year at baseline to an impressive 7.24 cm/year in the first year (p<0.001). These outcomes not only reinforce the efficacy of VOXZOGO but also indicate its potential for approval as BioMarin plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration before the end of the year.

Promising Results for VOXZOGO®

The encouraging results have been a focal point for BioMarin, with Executive Vice President Greg Friberg, M.D., emphasizing the treatment's capability to improve growth outcomes while illustrating a favorable safety profile. This aligns with the successful data from the CANOPY-HCH-3 Phase 3 study, enhancing confidence in the drug's future in the pediatric growth disorder market. Furthermore, BioMarin unveils new Phase 1 results for its investigational candidate BMN 333, a long-acting C-type natriuretic peptide (CNP) treatment aimed at achondroplasia. The study indicates that BMN 333 can potentially be administered weekly, achieving over 13 times the exposure to free CNP compared to existing long-acting agents, making it a significant contender for standard care.

Advancing Treatments for Growth Disorders

In conclusion, the advancements in both VOXZOGO and BMN 333 showcase BioMarin's strong commitment to delivering innovative treatments for children suffering from growth-related conditions. With promising clinical outcomes backing their potential, these products encourage a new horizon for patients while bolstering BioMarin’s position in the biotechnology sector dedicated to rare diseases. As patient enrollment for the BMN 333 study commenced in April, it underscores the company's proactive approach in expanding its pipeline and fulfilling unmet medical needs in this niche area of healthcare.